RESP DRUGS
Asthma characterised by
airway inflammation t
episodic reversible broncho spasm
Immediate broncho constriction mediated by several mediator
Cytokines l enzymes produce inflammation that leads to
bronchial hyperactivity to various stimuli
, Classification of asthma meds
A Symptomatic Broncho dilators
B 2 adrenoceptor agonists C short acting e.g salbutamol
or
long acting e.g Sal meter oh formeterd
Anti
cholinergic s e g I patropium bromide
Xanthin es e g Theophylline
B Prophylactic Prevent inflammation
Inhaled corticosteroids e
g Beclometasone Fluitcason
Budesonide
Xanthines Debatable
NB Anti inflammatories treat inflammation has a
fair overlap with prophylactics
Beta 2 agonist mechanism of action
I 2
3
4 5
Asthma characterised by
airway inflammation t
episodic reversible broncho spasm
Immediate broncho constriction mediated by several mediator
Cytokines l enzymes produce inflammation that leads to
bronchial hyperactivity to various stimuli
, Classification of asthma meds
A Symptomatic Broncho dilators
B 2 adrenoceptor agonists C short acting e.g salbutamol
or
long acting e.g Sal meter oh formeterd
Anti
cholinergic s e g I patropium bromide
Xanthin es e g Theophylline
B Prophylactic Prevent inflammation
Inhaled corticosteroids e
g Beclometasone Fluitcason
Budesonide
Xanthines Debatable
NB Anti inflammatories treat inflammation has a
fair overlap with prophylactics
Beta 2 agonist mechanism of action
I 2
3
4 5
